Fiona F Yu from Clive, IA, age 46

Resumes

Fiona Yu

view source

Fiona Yu

view source

Fiona Zhixian Yu

view source

Fiona Yu Elmhurst, NY

view source

Work:

KATIE MOSSMAN STUDIO

Sep 2014 to 2000
Intern BELLWETHER HR CONSULTING CO., LTD

Sep 2012 to Jun 2013
Associate Consultant INDUSTRIAL AND COMMERCIAL BANK OF CHINA (ICBC)

Mar 2012 to Jul 2012
Bank Teller GABRIEL PARADISE ENGLISH CLUB

Mar 2011 to Aug 2011
Teaching Assistant YOUTH LEAGUE COMMITTE, STUDENT UNION

Sep 2009 to Jul 2010
Vice Director STUDENT UNION

Sep 2008 to Jul 2009
Secretary

Education:

FORDHAM UNIVERSITY, GRADUATE SCHOOL OF BUSINESS ADMINISTRATION
New York, NY
2014
Master in Business Enterprise Shanghai Normal University Tianhua College
Jul 2012
Bachelor in English

Skills:

Language: Fluent in English, Mandarin, base Japanese, French Computer: Microsoft Office

Fiona Yu Berkeley, CA

view source

Work:

ING Investment Management
Hong Kong, Hong Kong Island
Jun 2012 to Aug 2012
Summer Intern, Business Development & Marketing Department

Education:

University of California-Berkeley
Berkeley, CA
2011 to 2013
Bachelor of Arts in Economics, Statistics Foothill College
Los Altos Hills, CA
Jun 2011
Accounting & Economics

Skills:

Data Analysis, Programming, Microsoft Excel, PowerPoint, R and STATA programming

Us Patents

Antidiabetic Bicyclic Compounds
view source
US Patent:

20070265332, Nov 15, 2007
Filed:

May 11, 2007
Appl. No.:

11/801841
Inventors:

Min Ge - Edison NJ, US
Jiafang He - Dayton NJ, US
Fiona Wai Yu Lau - Edgewater NJ, US
Songnian Lin - Monroe NJ, US
Weiguo Liu - Princeton NJ, US
Shawn P. Walsh - Bridgewater NJ, US
Lihu Yang - Edison NJ, US
International Classification:

A61K 31/381
A61K 31/343
A61K 31/192
A61K 31/195
US Classification:

514443, 514468, 514569, 549 44, 549458, 562452, 562466, 514567
Abstract:

Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.